Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
GRPR
acetate buffer stability
canine serum stability
gastrin-releasing peptide receptor
human serum stability
imaging pharmaceuticals
in-vitro stability
mouse serum stability
radiolabeling
radiotracers
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
08 Aug 2019
08 Aug 2019
Historique:
received:
10
05
2019
revised:
24
07
2019
accepted:
06
08
2019
entrez:
11
8
2019
pubmed:
11
8
2019
medline:
10
1
2020
Statut:
epublish
Résumé
The prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) are identified as important targets on prostate cancer. Receptor-targeting radiolabeled imaging pharmaceuticals with high affinity and specificity are useful in studying and monitoring biological processes and responses. Two potential imaging pharmaceuticals, AMBA agonist (where AMBA = DO3A-CH2CO-G-[4-aminobenzyl]- Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH
Identifiants
pubmed: 31398865
pii: molecules24162878
doi: 10.3390/molecules24162878
pmc: PMC6720803
pii:
doi:
Substances chimiques
Biomarkers
0
Ligands
0
Radiopharmaceuticals
0
Receptors, Bombesin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Res. 1999 Mar 1;59(5):1152-9
pubmed: 10070977
J Pept Res. 1999 Mar;53(3):275-83
pubmed: 10231715
Eur J Nucl Med. 2000 Nov;27(11):1694-9
pubmed: 11105826
Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):247-58
pubmed: 12552343
J Nucl Med. 2003 May;44(5):823-31
pubmed: 12732685
Nucl Med Biol. 2003 Nov;30(8):861-8
pubmed: 14698790
Cancer Res. 2004 Sep 15;64(18):6707-15
pubmed: 15374988
J Med Chem. 2005 Jan 13;48(1):100-10
pubmed: 15634004
J Nucl Med. 2006 Mar;47(3):375-7
pubmed: 16513604
J Nucl Med. 2006 Jul;47(7):1144-52
pubmed: 16818949
Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):95-100
pubmed: 16909223
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
Trends Pharmacol Sci. 1991 Jan;12(1):13-9
pubmed: 1706545
Appl Radiat Isot. 2008 Apr;66(4):497-505
pubmed: 18178448
J Nucl Med. 2008 Feb;49(2):318-26
pubmed: 18199616
Bioconjug Chem. 2008 Oct;19(10):2040-8
pubmed: 18808168
Methods. 2009 Jun;48(2):161-77
pubmed: 19324088
Clin Cancer Res. 2009 Aug 15;15(16):5240-9
pubmed: 19671861
Biochemistry. 2010 Feb 23;49(7):1364-76
pubmed: 20102226
Nucl Med Biol. 2010 Apr;37(3):365-70
pubmed: 20346876
Appl Radiat Isot. 2010 Dec;68(12):2285-92
pubmed: 20638858
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):97-107
pubmed: 20717822
Radiology. 2011 Jun;259(3):852-61
pubmed: 21493787
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S11-30
pubmed: 22388624
Q J Nucl Med Mol Imaging. 2012 Oct;56(5):447-58
pubmed: 23069924
Am J Nucl Med Mol Imaging. 2013;3(1):85-96
pubmed: 23342303
Bioconjug Chem. 2013 Jul 17;24(7):1144-53
pubmed: 23763444
PLoS One. 2013 Dec 03;8(12):e81932
pubmed: 24312607
Am J Nucl Med Mol Imaging. 2014 Sep 06;4(6):580-601
pubmed: 25250207
J Nucl Med. 2014 Dec;55(12):2050-6
pubmed: 25413139
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Clin Nucl Med. 2015 Aug;40(8):e386-91
pubmed: 26053708
Bioconjug Chem. 2016 Mar 16;27(3):790-8
pubmed: 26837664
Cancer Biother Radiopharm. 2017 Feb;32(1):24-32
pubmed: 28186846
J Nucl Med. 2017 Aug;58(8):1270-1277
pubmed: 28408532
J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S
pubmed: 28864607
Bioconjug Chem. 2018 Feb 21;29(2):410-419
pubmed: 29254329
Prostate. 2018 Jul 11;:
pubmed: 29992622
Pharmacol Ther. 1987;34(1):99-109
pubmed: 3310046
Peptides. 1982 May-Jun;3(3):559-63
pubmed: 6181494
Int J Cancer. 1994 May 15;57(4):574-80
pubmed: 7910153